References

References: Chapter 14 · What the Mothers Never Chose

  1. Herbst AL, Ulfelder H, Poskanzer DC. 'Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women.' NEJM 284(15):878-881, 1971.
  2. CDC. 'About DES (Diethylstilbestrol)' (documents the 1971 FDA advisory and history).
  3. Dodds EC, Lawson W. Synthetic oestrogenic agents without the phenanthrene nucleus. Nature 137:996 (1936).
  4. Vogel SA. The politics of plastics: the making and unmaking of bisphenol A 'safety'. American Journal of Public Health 99(S3):S559-S566 (2009).
  5. Hoover RN et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. New England Journal of Medicine 365(14):1304-1314 (2011).
  6. National Cancer Institute. Diethylstilbestrol (DES) Exposure and Cancer (fact sheet).
  7. Milligan SR, Khan O, Nash M. Competitive binding of xenobiotic oestrogens to rat alpha-fetoprotein and to sex steroid binding proteins. Gen Comp Endocrinol 112(1):89-95, 1998.
  8. Kuiper GGJM, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139(10):4252-4263, 1998.
  9. Colborn T, vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environmental Health Perspectives 101(5):378-384, 1993.
  10. Acconcia F, Pallottini V, Marino M. Molecular mechanisms of action of BPA. Dose-Response 13(4), 2015. (PMC4679188)
  11. Newbold RR. Lessons learned from perinatal exposure to diethylstilbestrol. Toxicology and Applied Pharmacology 199(2):142-150, 2004.
  12. Caldwell DJ et al. Derivation of an aquatic predicted no-effect concentration for the synthetic hormone 17-alpha-ethinyl estradiol. Environmental Science & Technology 44(4):1480-1486, 2010.
  13. Dodds EC, Goldberg L, Lawson W, Robinson R. Oestrogenic activity of certain synthetic compounds. Nature 141:247-248, 1938.
  14. Embryo Project Encyclopedia (Arizona State University): Edward Charles Dodds (1899-1973).
  15. Embryo Project Encyclopedia (Arizona State University): Diethylstilbestrol (DES) in the US.
  16. Reed CE, Fenton SE. Exposure to diethylstilbestrol during sensitive life stages: a legacy of heritable health effects. Birth Defects Research Part C 99(2):134-146, 2013.
  17. Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the long-term health effects. Annals of Internal Medicine 122(10):778-788, 1995.
  18. Apfel RJ, Fisher SM. To Do No Harm: DES and the Dilemmas of Modern Medicine. Yale University Press, 1984.
  19. Dieckmann WJ, Davis ME, Rynkiewicz LM, Pottinger RE. Does the administration of diethylstilbestrol during pregnancy have therapeutic value? American Journal of Obstetrics and Gynecology 66(5):1062-1081, 1953.
  20. UChicago Medicine. The DES saga: death risk high for young women exposed in utero.
  21. Miller RK, Heckmann ME, McKenzie RC. Diethylstilbestrol: placental transfer, metabolism, covalent binding and fetal distribution in the Wistar rat. J Pharmacol Exp Ther 220(2):358-365, 1982.
  22. Reed CE, Fenton SE. Exposure to diethylstilbestrol during sensitive life stages. Birth Defects Research Part C 99(2):134-146, 2013.
  23. Latini G, De Felice C, Presta G, et al. In utero exposure to di-(2-ethylhexyl)phthalate and duration of human pregnancy. Environ Health Perspect. 2003;111(14):1783-1785.
  24. Mose T, Mortensen GK, Hedegaard M, Knudsen LE. Phthalate monoesters in perfusate from a dual placenta perfusion system, the placenta tissue and umbilical cord blood. Reprod Toxicol. 2007;23(1):83-91.
  25. Saunders NR, Liddelow SA, Dziegielewska KM. Barrier mechanisms in the developing brain. Front Pharmacol 3:46, 2012.
  26. Ek CJ, Dziegielewska KM, Habgood MD, Saunders NR. Barriers in the developing brain and Neurotoxicology. NeuroToxicology 33(3):586-604, 2012.
  27. Baker TG, A quantitative and cytological study of germ cells in human ovaries, Proc R Soc Lond B Biol Sci 158:417-433, 1963 (PMID 14070052)
  28. Wallace WHB, Kelsey TW, Human ovarian reserve from conception to the menopause, PLoS ONE 5(1):e8772, 2010
  29. Anway MD, Cupp AS, Uzumcu M, Skinner MK, Epigenetic transgenerational actions of endocrine disruptors and male fertility, Science 308(5727):1466-1469, 2005 (PMID 15933200)
  30. Manikkam M et al., Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations, PLoS ONE 8(1):e55387, 2013
  31. Johns Hopkins Medicine, 'Calculating a Due Date,' hopkinsmedicine.org/health/wellness-and-prevention/calculating-a-due-date.
  32. 'Naegele's rule and the length of pregnancy: a review,' PubMed PMID 33079400, 2020.
  33. Titus-Ernstoff L, Troisi R, Hatch EE, et al. Birth defects in the sons and daughters of women who were exposed in utero to diethylstilbestrol (DES). Int J Androl 33(2):377-384, 2010.
  34. Newbold RR, Padilla-Banks E, Jefferson WN. Developmental exposure to endocrine disruptors and the obesity epidemic. Reprod Toxicol 23(3):290-296, 2007.
  35. European Environment Agency. Late Lessons from Early Warnings: Science, Precaution, Innovation (EEA Report No 1/2013).
  36. Markowitz G, Rosner D. Lead Wars: The Politics of Science and the Fate of America's Children. University of California Press (2013).